CureVac N.V., a biotech company specializing in mRNA-based medicines, announced the resolution of its patent litigation with Pfizer and BioNTech regarding mRNA-based COVID-19 vaccines. Under the settlement, CureVac and its affiliate GSK will receive a total payment of $740 million, along with single-digit royalties on future U.S. sales of COVID-19 vaccines. Additionally, CureVac will receive $50 million from GSK by monetizing a portion of U.S. product royalties from a prior agreement. The settlement includes granting Pfizer and BioNTech a non-exclusive license to manufacture and sell mRNA-based COVID-19 and influenza products in the U.S., which will expand to a global license following BioNTech's acquisition of CureVac. This acquisition, announced earlier in June 2025, is set to proceed as planned, subject to regulatory approval.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.